Subscribe To
ARMP / After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)
ARMP News
By Zacks Investment Research
August 22, 2023
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why
Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage cand more_horizontal
By Zacks Investment Research
May 11, 2023
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.29. This com more_horizontal
By Zacks Investment Research
November 28, 2022
After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, more_horizontal
By PRNewsWire
November 28, 2022
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
MARINA DEL REY, Calif. , Nov. 28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnolog more_horizontal